Bcl-2-like protein 2 mRNA (BCL2L2 mRNA)

BCL2L2 mRNA encodes the Bcl-2-like protein 2, commonly known as Bcl-w, which is a potent anti-apoptotic member of the Bcl-2 family (UniProt Q92843). This protein plays a critical role in maintaining cell survival by sequestering pro-apoptotic proteins such as BAX and BAK, thereby preventing mitochondrial outer membrane permeabilization and the subsequent release of cytochrome c (NCBI Gene ID: 599). In various human malignancies, including colorectal, gastric, and lung cancers, BCL2L2 mRNA is frequently overexpressed, which contributes to tumor cell survival and resistance to chemotherapy-induced apoptosis (PubMed: 21505400). Beyond its role in cancer, Bcl-w is essential for normal physiological processes such as spermatogenesis (PubMed: 9154821). As a therapeutic target, BCL2L2 mRNA is approached using RNA-based strategies such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) designed to specifically silence its expression. By downregulating Bcl-w levels, these interventions aim to restore the apoptotic potential of cancer cells and enhance their sensitivity to other anti-cancer treatments. While small molecule inhibitors like Navitoclax target the Bcl-w protein directly, mRNA-directed strategies offer a highly specific approach to modulating the abundance of this pro-survival factor.

Other names

Bcl-w mRNABCL2L2 transcriptBcl2-L-2 mRNAPPP1R51 mRNABcl-2-like 2 mRNA

Antisense-mediated degradation or RNA interference (RNAi) targeting the BCL2L2 transcript to prevent translation of the Bcl-w protein.